Innovent Biologics Inc (6IB) - Cash Flow Conversion Efficiency

Latest as of June 2023: -0.029x

Based on the latest financial reports, Innovent Biologics Inc (6IB) has a cash flow conversion efficiency ratio of -0.029x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-311.45 Million ≈ $-364.11 Million USD) by net assets (€10.78 Billion ≈ $12.61 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 6IB company net worth for the company's overall valuation and market capitalisation.

Innovent Biologics Inc - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Innovent Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Innovent Biologics Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Innovent Biologics Inc ranked by their cash flow conversion efficiency. Explore 6IB cash to earnings ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Woori Financial Group Inc KO:316140	0.118x
OMV AG ADR 1 F:OMVI	0.036x
Aluminum Corp of China Ltd SHG:601600	0.065x
Suncorp Group Ltd AU:SUNPH	-0.042x
POSCO Holdings Inc F:PKX	0.031x
Yantai Jereh Oilfield Services Group Co Ltd SHE:002353	-0.009x
Brambles Ltd AU:BXB	0.287x
POSCO Holdings Inc NYSE:PKX	0.004x

Annual Cash Flow Conversion Efficiency for Innovent Biologics Inc (2016–2025)

The table below shows the annual cash flow conversion efficiency of Innovent Biologics Inc from 2016 to 2025. View today's stock price for Innovent Biologics Inc for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€19.36 Billion ≈ $22.63 Billion	€10.00 Billion ≈ $11.69 Billion	0.517x	+426.62%
2024-12-31	€13.12 Billion ≈ $15.34 Billion	€1.29 Billion ≈ $1.50 Billion	0.098x	+731.56%
2023-12-31	€12.53 Billion ≈ $14.65 Billion	€147.81 Million ≈ $172.81 Million	0.012x	+106.60%
2022-12-31	€10.73 Billion ≈ $12.54 Billion	€-1.92 Billion ≈ $-2.24 Billion	-0.179x	+8.77%
2021-12-31	€10.33 Billion ≈ $12.08 Billion	€-2.02 Billion ≈ $-2.37 Billion	-0.196x	-459.30%
2020-12-31	€8.78 Billion ≈ $10.26 Billion	€-307.69 Million ≈ $-359.72 Million	-0.035x	+89.99%
2019-12-31	€4.76 Billion ≈ $5.56 Billion	€-1.66 Billion ≈ $-1.95 Billion	-0.350x	-45.07%
2018-12-31	€4.19 Billion ≈ $4.90 Billion	€-1.01 Billion ≈ $-1.18 Billion	-0.241x	-179.49%
2017-12-31	€-1.62 Billion ≈ $-1.90 Billion	€-492.27 Million ≈ $-575.52 Million	0.303x	-19.89%
2016-12-31	€-958.22 Million ≈ $-1.12 Billion	€-362.99 Million ≈ $-424.38 Million	0.379x	--

About Innovent Biologics Inc

F:6IB Germany Biotechnology

Market Cap

$20.92 Billion

€17.89 Billion EUR

Market Cap Rank

#1417 Global

#318 in Germany

Share Price

€10.28

Change (1 day)

-1.21%

52-Week Range

€7.96 - €11.96

All Time High

€11.96